RecruitingNot ApplicableNCT06989775

BoxX-NoAF Clinical Trial

EnCompass Clamp and the AtriClip in Box Lesion and Left Atrial Appendage EXclusion Procedure for the Prevention of New Onset of Atrial Fibrillation


Sponsor

AtriCure, Inc.

Enrollment

960 participants

Start Date

Oct 24, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.


Eligibility

Min Age: 65 Years

Inclusion Criteria2

  • Planned and clinically indicated for cardiac surgical procedure requiring cardiac bypass and opening of the pericardium
  • Age ≥ 65 years and CHA2DS2-VASc ≥ 3

Exclusion Criteria20

  • Documented history of atrial fibrillation or atrial flutter anytime prior to the cardiac surgery
  • Prior procedure involving opening the pericardium or entering the pericardial space
  • Patients undergoing off-pump surgery
  • Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
  • Presence of a permanent pacemaker
  • Infiltrative cardiomyopathies (i.e. amyloidosis)
  • Planned cardiac surgical procedure using non-sternotomy approaches
  • Patients whose planned procedure is a heart transplant or implantation of any long-term ventricular assist devices
  • Presence of ventricular arrhythmia
  • Active endocarditis
  • NYHA Class IV heart failure symptoms
  • Preoperative need for an intra-aortic ballon pump or intravenous inotropes
  • Active systemic infection at the time of cardiac surgery requiring antibiotics
  • Known allergy to Nitinol or nickel sensitivity
  • Known medical condition with expected survival of less than 1 year
  • Other comorbidities that in the Investigator's opinion make the subject unsuitable candidate to complete the protocol required intervention or visits
  • Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial
  • Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
  • Pregnancy
  • Known severe symptomatic carotid disease

Interventions

DEVICEIsolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System

Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery


Locations(10)

St. Bernards Medical Center

Jonesboro, Arkansas, United States

Morton Plant Hospital - BayCare Health System, Inc.

Clearwater, Florida, United States

St. Joseph's Hospital - BayCare Health System, Inc.

Clearwater, Florida, United States

Orlando Health, Inc.

Orlando, Florida, United States

Wellstar Health System

Marietta, Georgia, United States

Corewell Health

Grand Rapids, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

New York Presbyterian Hospital/Columbia University Irving Medical Center

New York, New York, United States

Ascension Saint Thomas

Nashville, Tennessee, United States

Hamilton General Hospital

Hamilton, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989775


Related Trials